详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Cerebrospinal fluid LMO4 as a synaptic biomarker linked to Alzheimer's disease pathology and cognitive decline

15| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]The First Clinical Medical School, Hebei North University, Zhangjiakou, China. [2]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China. [3]Department of Neurosurgery, The First Affiliated Hospital of Hebei North University, Hebei, Zhangjiakou, China. [4]Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China.

出处：

DOI：

ISSN：

关键词： Alzheimer’s disease amyloid-β LMO4 tau therapeutic strategy

摘要：

BackgroundLIM-domain-only 4 (LMO4) is involved in neurodevelopment and synaptic plasticity, but its role in the pathogenesis of Alzheimer's disease (AD) remains unclear.ObjectiveTo investigate the association between cerebrospinal fluid (CSF) LMO4 levels and core AD biomarkers, neurodegeneration, and cognitive decline.MethodsWe included 703 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Associations between CSF LMO4 and AD biomarkers (Aβ42, Ptau181, amyloid PET) and postmortem neuropathology were evaluated. We also explored cross-sectional and longitudinal associations between CSF LMO4 and neurodegeneration and cognitive function. Receiver operating characteristic (ROC) analysis assessed the diagnostic accuracy of CSF LMO4 in distinguishing Aβ-positive from Aβ-negative participants and amyloid PET-confirmed AD cases. Mediation analysis explored the potential mediating role of CSF LMO4 between Aβ pathology and tau pathology.ResultsLMO4 levels were decreased in participants with abnormal Aβ levels and cognitive impairment. Lower CSF LMO4 levels were associated with increased Aβ and tau pathology, brain atrophy, cognitive decline, and postmortem neuropathology. CSF LMO4 partially mediated the relationship between Aβ and tau pathology and demonstrated acceptable discriminative ability in distinguishing Aβ-positive from Aβ-negative participants and amyloid PET-confirmed AD from non-AD cases.ConclusionsCSF LMO4 plays a crucial role in the pathogenesis and progression of AD and may represent a potential therapeutic target for AD treatment.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 3 区医学

小类 | 3 区神经科学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区神经科学

JCR分区：

出版当年[2023]版：

Q2 NEUROSCIENCES

最新[2023]版：

Q2 NEUROSCIENCES

影响因子： 3.4 最新[2023版] 4.2 最新五年平均 3.4 出版当年[2023版] 4.2 出版当年五年平均 4 出版前一年[2022版]

第一作者：

第一作者机构： [1]The First Clinical Medical School, Hebei North University, Zhangjiakou, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Neuroinflammation and Neuroimmunomodulation in Alzheimer’s Disease [2]Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline [3]Sulforaphane Reverses the Amyloid-β Oligomers Induced Depressive-Like Behavior. [4]Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment [5]阿尔茨海默病：自噬与β淀粉样肽关系的研究进展 [6]Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment [7]The Large Ectodomain of APP Prevents APP from being Directly Cleaved by γ-Secretase [8]Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential. [9]FUBP3 mediates the amyloid-β-induced neuronal NLRP3 expression [10]Detection of plasma Aβ seeding activity by a newly developed analyzer for diagnosis of Alzheimer's disease.